Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China.
Reproductive Medicine Center, Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China.
Cancer Med. 2022 Dec;11(24):5037-5049. doi: 10.1002/cam4.4801. Epub 2022 May 15.
High-risk human papillomavirus (hrHPV) infection is a key factor that alters cervicovaginal microbiota patterns and causes cervical intraepithelial neoplasias (CINs) or even cervical cancer. Although local excisional treatment can clear hrHPV infection and restore the cervicovaginal microbiota, it is unclear which cervicovaginal microbiota represents recovery. Our objective was to describe the cervicovaginal microbiota before and after treatments and to assess the association between the microbiota and HPV persistence.
A cohort of 91 participants was classified into four groups (healthy control women and HPV16-infected women with CIN I, CIN II/III, and squamous cell carcinoma [SCC]). Endocervical swabs were collected 3 months prior to treatment and at 3 months post-treatment for bacterial 16S rRNA gene pyrosequencing and for HPV DNA testing. There was an increase in the number of Lactobacillus bacterial species present after the clinical treatments, and the community state type (CST) profiles were shifted from dysbiotic CSTs II and IV to Lactobacillus-dominated CSTs I and III. Specifically, the composition of Geobacter and Prevotella before treatment and Lactobacillus secaliphilus after treatment might have been related to CIN I, the composition of Burkholderia before treatment and Lactobacillus iners after treatment might have been related to CIN II/III, and the composition of Atopobium and Aerococcus before treatment and Bacilli after treatment might have been related to SCC. Further functional predictions revealed that the composition differences were linked to infectious disease- and cancer-related genes.
Our study provides an illustration of the changes in CSTs and the cervicovaginal microbiota before and after HPV16 clearance in each disease state.
高危型人乳头瘤病毒（hrHPV）感染是改变宫颈阴道微生物群模式并导致宫颈上皮内瘤变（CIN）甚至宫颈癌的关键因素。虽然局部切除治疗可以清除 hrHPV 感染并恢复宫颈阴道微生物群，但尚不清楚哪种宫颈阴道微生物群代表恢复。我们的目的是描述治疗前后的宫颈阴道微生物群，并评估微生物群与 HPV 持续存在之间的关联。
我们对 91 名参与者进行了分类，分为四组（健康对照组妇女和 HPV16 感染的 CIN I、CIN II/III 和鳞状细胞癌 [SCC] 妇女）。在治疗前 3 个月和治疗后 3 个月采集宫颈阴道拭子，进行细菌 16S rRNA 基因焦磷酸测序和 HPV DNA 检测。在临床治疗后，存在的乳杆菌细菌种类数量增加，群落状态类型（CST）谱从失调的 CSTs II 和 IV 转变为以乳杆菌为主的 CSTs I 和 III。具体而言，治疗前的 Geobacter 和 Prevotella 以及治疗后的 Lactobacillus secaliphilus 的组成可能与 CIN I 相关，治疗前的 Burkholderia 和治疗后的 Lactobacillus iners 的组成可能与 CIN II/III 相关，治疗前的 Atopobium 和 Aerococcus 以及治疗后的 Bacilli 的组成可能与 SCC 相关。进一步的功能预测表明，组成差异与传染病和癌症相关基因有关。
我们的研究提供了在每种疾病状态下 HPV16 清除前后 CST 和宫颈阴道微生物群变化的说明。
